Search

Your search keyword '"Bolen, Christopher R."' showing total 197 results
Start Over Author "Bolen, Christopher R."
197 results on '"Bolen, Christopher R."'

2. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Author

Kater, Arnon P, Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R, Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, and Seymour, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Lymphoma, Genetics, Rare Diseases, Good Health and Well Being, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Bridged Bicyclo Compounds, Heterocyclic, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Karyopherins, Leukemia, Lymphocytic, Chronic, B-Cell, Mutation, Progression-Free Survival, Proto-Oncogene Proteins B-raf, Receptor, Notch1, Receptors, Cytoplasmic and Nuclear, Rituximab, Sulfonamides, Treatment Outcome, Tumor Suppressor Protein p53, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeIn previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics.Patients and methodsPatients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed.ResultsOf 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT.ConclusionEfficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

Published
2020

5. Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Author

Nowicka, Malgorzata, Hilton, Laura K., Ashton-Key, Margaret, Hargreaves, Chantal E., Lee, Chern, Foxall, Russell, Carter, Matthew J., Beers, Stephen A., Potter, Kathleen N., Bolen, Christopher R., Klein, Christian, Knapp, Andrea, Mir, Farheen, Rose-Zerilli, Matthew, Burton, Cathy, Klapper, Wolfram, Scott, David W., Sehn, Laurie H., Vitolo, Umberto, Martelli, Maurizio, Trneny, Marek, Rushton, Christopher K., Slack, Graham W., Farinha, Pedro, Strefford, Jonathan C., Oestergaard, Mikkel Z., Morin, Ryan D., and Cragg, Mark S.

Published
2021
Full Text
View/download PDF

6. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Author

Strefford, Jonathan C., Nowicka, Malgorzata, Hargreaves, Chantal E., Burton, Cathy, Davies, Andrew, Ganderton, Rosalind, Hiddemann, Wolfgang, Iriyama, Chisako, Klapper, Wolfram, Latham, Kate V., Martelli, Maurizio, Mir, Farheen, Parker, Helen, Potter, Kathleen N., Rose-Zerilli, Matthew J.J., Sehn, Laurie H., Trněný, Marek, Vitolo, Umberto, Bolen, Christopher R., Klein, Christian, Knapp, Andrea, Oestergaard, Mikkel Z., and Cragg, Mark S.

Published
2021
Full Text
View/download PDF

7. NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.

Author

Tabari, Ehsan, Lovejoy, Alexander F., Lin, Hai, Bolen, Christopher R., Lor Saelee, Seng, Lefkowitz, Joshua P., Kurtz, David M., Bottos, Alessia, Nielsen, Tina G., Parreira, Joana M., and Luong, Khai T.

Subjects
DIFFUSE large B-cell lymphomas, CIRCULATING tumor DNA, NUCLEOTIDE sequencing
Abstract

Personalized risk stratification and treatment may help improve outcomes among patients with diffuse large B-cell lymphoma (DLBCL). We developed a next-generation sequencing (NGS)-based method to assess a range of potential prognostic indicators, and evaluated it using pretreatment plasma samples from 310 patients with previously untreated DLBCL from the GOYA trial (NCT01287741). Variant calls and DLBCL subtyping with the plasma-based method were concordant with corresponding tissue-based methods. Patients with a tumor burden greater than the median (p =.003) and non-germinal center B-cell-like (non-GCB) DLBCL (p =.049) had worse progression-free survival than patients with a tumor burden less than the median or GCB DLBCL. Multi-factor assessment combining orthogonal features from a single pretreatment plasma sample has promise as a prognostic indicator in this setting (p =.085). This minimally invasive plasma-based NGS assay could enable comprehensive prognostic assessment of patients in a clinical setting, with greater accessibility than current methods. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Author

Klanova, Magdalena, Sehn, Laurie H., Bence-Bruckler, Isabelle, Cavallo, Federica, Jin, Jie, Martelli, Maurizio, Stewart, Douglas, Vitolo, Umberto, Zaja, Francesco, Zhang, Qingyuan, Mattiello, Federico, Sellam, Gila, Punnoose, Elizabeth A., Szafer-Glusman, Edith, Bolen, Christopher R., Oestergaard, Mikkel Z., Fingerle-Rowson, Guenter R., Nielsen, Tina, and Trneny, Marek

Published
2019
Full Text
View/download PDF

9. POSTER: IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

Author

Bartlett, Nancy L., primary, Sehn, Laurie H., additional, Matasar, Matthew, additional, Schuster, Stephen J., additional, Assouline, Sarit, additional, Giri, Pratyush, additional, Kuruvilla, John, additional, Canales, Miguel, additional, Dietrich, Sascha, additional, Fay, Keith, additional, Ku, Matthew, additional, Nastoupil, Loretta, additional, Wei, Michael C., additional, Yin, Shen, additional, To, Iris, additional, Huang, Huang, additional, Min, Juliana, additional, Bolen, Christopher R., additional, Penuel, Elicia, additional, and Budde, L. Elizabeth, additional

Published
2023
Full Text
View/download PDF

10. IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

Author

Bartlett, Nancy L., primary, Sehn, Laurie H., additional, Matasar, Matthew, additional, Schuster, Stephen J., additional, Assouline, Sarit, additional, Giri, Pratyush, additional, Kuruvilla, John, additional, Canales, Miguel, additional, Dietrich, Sascha, additional, Fay, Keith, additional, Ku, Matthew, additional, Nastoupil, Loretta, additional, Wei, Michael C., additional, Yin, Shen, additional, To, Iris, additional, Huang, Huang, additional, Min, Juliana, additional, Bolen, Christopher R., additional, Penuel, Elicia, additional, and Budde, L. Elizabeth, additional

Published
2023
Full Text
View/download PDF

11. Long‐term follow‐up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T‐cells in follicular lymphoma patients treated by rituximab‐maintenance regimen

Author

Laurent, Camille, primary, Flores, Maria, additional, Chartier, Loïc, additional, Huet, Sarah, additional, Bolen, Christopher R., additional, Venstrom, Jeffrey M., additional, Chassagne‐Clément, Catherine, additional, Dartigues‐Cuilléres, Peggy, additional, Charlotte, Fréderic, additional, Tesson, Bruno, additional, Salles, Gilles, additional, Morschhauser, Franck, additional, and Xerri, Luc, additional

Published
2023
Full Text
View/download PDF

12. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients

Author

Xerri, Luc, Huet, Sarah, Venstrom, Jeffrey M., Szafer-Glusman, Edith, Fabiani, Bettina, Canioni, Danielle, Chassagne-Clément, Catherine, Dartigues-Cuilléres, Peggy, Charlotte, Fréderic, Laurent, Camille, Gelas-Dore, Benedicte, Bolen, Christopher R., Punnoose, Elizabeth, Bouabdallah, Reda, Brice, Pauline, Morschhauser, Franck, Cartron, Guillaume, Olive, Daniel, and Salles, Gilles

Published
2017
Full Text
View/download PDF

14. Supplementary Table S3 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Author

Klanova, Magdalena, primary, Oestergaard, Mikkel Z., primary, Trněný, Marek, primary, Hiddemann, Wolfgang, primary, Marcus, Robert, primary, Sehn, Laurie H., primary, Vitolo, Umberto, primary, Bazeos, Alexandra, primary, Goede, Valentin, primary, Zeuner, Harald, primary, Knapp, Andrea, primary, Sahin, Deniz, primary, Spielewoy, Nathalie, primary, Bolen, Christopher R., primary, Cardona, Andres, primary, Klein, Christian, primary, Venstrom, Jeffrey M., primary, Nielsen, Tina, primary, and Fingerle-Rowson, Günter, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figures from Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

Author

Hamid, Omid, primary, Molinero, Luciana, primary, Bolen, Christopher R., primary, Sosman, Jeffrey A., primary, Muñoz-Couselo, Eva, primary, Kluger, Harriet M., primary, McDermott, David F., primary, Powderly, John D., primary, Sarkar, Indrani, primary, Ballinger, Marcus, primary, Fassò, Marcella, primary, O'Hear, Carol, primary, Chen, Daniel S., primary, Hegde, Priti S., primary, and Hodi, F. Stephen, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data Tables from Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

Author

Hamid, Omid, primary, Molinero, Luciana, primary, Bolen, Christopher R., primary, Sosman, Jeffrey A., primary, Muñoz-Couselo, Eva, primary, Kluger, Harriet M., primary, McDermott, David F., primary, Powderly, John D., primary, Sarkar, Indrani, primary, Ballinger, Marcus, primary, Fassò, Marcella, primary, O'Hear, Carol, primary, Chen, Daniel S., primary, Hegde, Priti S., primary, and Hodi, F. Stephen, primary

Published
2023
Full Text
View/download PDF

18. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states

Author

Furman, David, Chang, Junlei, Lartigue, Lydia, Bolen, Christopher R, Haddad, François, Gaudilliere, Brice, Ganio, Edward A, Fragiadakis, Gabriela K, Spitzer, Matthew H, Douchet, Isabelle, Daburon, Sophie, Moreau, Jean-François, Nolan, Garry P, Blanco, Patrick, Déchanet-Merville, Julie, Dekker, Cornelia L, Jojic, Vladimir, Kuo, Calvin J, Davis, Mark M, and Faustin, Benjamin

Subjects
Inflammasomes -- Health aspects, Elderly -- Genetic aspects -- Health aspects, Immune response -- Genetic aspects, Gene expression -- Health aspects, Biological sciences, Health
Abstract

Low-grade, chronic inflammation has been associated with many diseases of aging, but the mechanisms responsible for producing this inflammation remain unclear. Inflammasomes can drive chronic inflammation in the context of an infectious disease or cellular stress, and they trigger the maturation of interleukin-1[beta] (IL-1[beta]). Here we find that the expression of specific inflammasome gene modules stratifies older individuals into two extremes: those with constitutive expression of IL-1[beta], nucleotide metabolism dysfunction, elevated oxidative stress, high rates of hypertension and arterial stiffness; and those without constitutive expression of IL-1[beta], who lack these characteristics. Adenine and N[sup.4]-acetylcytidine, nucleotide-derived metabolites that are detectable in the blood of the former group, prime and activate the NLRC4 inflammasome, induce the production of IL-1[beta], activate platelets and neutrophils and elevate blood pressure in mice. In individuals over 85 years of age, the elevated expression of inflammasome gene modules was associated with all-cause mortality. Thus, targeting inflammasome components may ameliorate chronic inflammation and various other age-associated conditions., Author(s): David Furman (corresponding author) [1, 2]; Junlei Chang [3]; Lydia Lartigue [4]; Christopher R Bolen [5]; François Haddad [6]; Brice Gaudilliere [5]; Edward A Ganio [5]; Gabriela K Fragiadakis [...]

Published
2017
Full Text
View/download PDF

19. Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study

Author

Morschhauser, Franck, Leung, Wilfred, Raghavan, Vibha, Lenz, Georg, Jardin, Fabrice, Herrera, Alex F., Sehn, Laurie H., Sharman, Jeff P., Flowers, Christopher R., Friedberg, Jonathan W., Trněný, Marek, Tilly, Hervé, Herbaux, Charles, Tracy, Samuel, Bolen, Christopher R., Harris, Will, Hirata, Jamie H., Lee, Calvin, Jiang, Yanwen, Lee Batlevi, Connie, and Salles, Gilles

Published
2024
Full Text
View/download PDF

20. Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.

Author

Schuster, Stephen J., primary, Huw, Ling-Yuh, additional, Bolen, Christopher R., additional, Assouline, Sarit E., additional, Bartlett, Nancy L., additional, Budde, L Elizabeth, additional, Matasar, Matthew J., additional, Koeppen, Hartmut, additional, Piccione, Emily C., additional, Wilson, Deanna, additional, Wei, Michael C., additional, Yin, Shen, additional, and Penuel, Elicia M., additional

Published
2022
Full Text
View/download PDF

21. Additional file 1 of Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma

Author

Kim, Eugene, Jiang, Yanwen, Xu, Tao, Bazeos, Alexandra, Knapp, Andrea, Bolen, Christopher R., Humphrey, Kathryn, Nielsen, Tina G., Penuel, Elicia, and Paulson, Joseph N.

Abstract

Additional file 1: Supplementary Methods and Results. Supplementary Table S1. Baseline disease characteristics of patients in the BEP and ITT study populations in GOYA and CAVALLI. Supplementary Table S2. Confusion matrix for Random Forest training model. Supplementary Table S3. A. CAVALLI ethics committees (EC) and/or institutional review boards (IRB) of participating centers. B. GOYA ethics committees (EC) and/or institutional review boards (IRB) of participating centers. Supplementary Figure S1. NMF-defined clusters in CAVALLI and their association with cell-of-origin. Supplementary Figure S2. Kaplan-Meier curves of PFS for NMF high- and low-risk prognostic groups in GOYA according to (A) treatment and (B) cell-of-origin (activated B-cell-like vs germinal center B-cell-like). Supplementary Figure S3. Kaplan-Meier curve of PFS for the BCL2/EZH2 versus MYD88/CD798 clusters in CAVALLI (de novo NMF clustering). Supplementary Figure S4. Training of a Random Forest model on NMF cluster labels in GOYA onto CAVALLI. (A) Clustering of gene features of predicted GOYA NMF groups onto CAVALLI. (B) Kaplan-Meier curves of PFS for predicted GOYA NMF groups in CAVALLI. Supplementary Figure S5. Kaplan-Meier curves of PFS for GOYA and CAVALLI. Supplementary Figure S6. Differential expression and pathway analysis of NMF highrisk vs low-risk patients in GOYA. (A) Volcano plot of all genes for patients with NMF risk categorization and RNA-Seq data. Limma was used to determine differential expression with no covariate adjustment. Labelled points outside of the red dotted lines indicate genes with a false discovery rate 1. (B) Pathways with false discovery rate

Published
2022
Full Text
View/download PDF

22. A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA

Author

Kostakoglu, Lale, primary, Dalmasso, Federico, additional, Berchialla, Paola, additional, Pierce, Larry A., additional, Vitolo, Umberto, additional, Martelli, Maurizio, additional, Sehn, Laurie H., additional, Trněný, Marek, additional, Nielsen, Tina G., additional, Bolen, Christopher R., additional, Sahin, Deniz, additional, Lee, Calvin, additional, El‐Galaly, Tarec Christoffer, additional, Mattiello, Federico, additional, Kinahan, Paul E., additional, and Chauvie, Stephane, additional

Published
2022
Full Text
View/download PDF

24. An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Author

Passerini, Verena, primary, Jurinovic, Vindi, additional, Bolen, Christopher R, additional, Knapp, Andrea, additional, Bottos, Alessia, additional, Richter, Julia, additional, Fitzgibbon, Jude, additional, Klapper, Wolfram, additional, Davies, Andrew, additional, Marcus, Robert, additional, von Bergwelt, Michael, additional, Nielsen, Tina, additional, Dreyling, Martin H., additional, Hiddemann, Wolfgang, additional, Unterhalt, Michael, additional, Hoster, Eva, additional, and Weigert, Oliver, additional

Published
2021
Full Text
View/download PDF

26. Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes

Author

Abbas, Hussein A., primary, Mohanty, Vakul, additional, Wang, Ruiping, additional, Huang, Yuefan, additional, Liang, Shaoheng, additional, Wang, Feng, additional, Zhang, Jianhua, additional, Qiu, Yihua, additional, Hu, Chenyue W., additional, Qutub, Amina A., additional, Dail, Monique, additional, Bolen, Christopher R., additional, Daver, Naval, additional, Konopleva, Marina, additional, Futreal, Andrew, additional, Chen, Ken, additional, Wang, Linghua, additional, and Kornblau, Steven M., additional

Published
2021
Full Text
View/download PDF

27. Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Author

Bolen, Christopher R., primary, Mattiello, Federico, additional, Herold, Michael, additional, Hiddemann, Wolfgang, additional, Huet, Sarah, additional, Klapper, Wolfram, additional, Marcus, Robert, additional, Mir, Farheen, additional, Salles, Gilles, additional, Weigert, Oliver, additional, Nielsen, Tina, additional, Oestergaard, Mikkel Z., additional, and Venstrom, Jeffrey M., additional

Published
2021
Full Text
View/download PDF

30. Additional file 1 of A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

Author

Sehn, Laurie H., Martelli, Maurizio, Trněný, Marek, Wenxin Liu, Bolen, Christopher R., Knapp, Andrea, Sahin, Deniz, Sellam, Gila, and Vitolo, Umberto

Subjects
neoplasms
Abstract

Additional file 1: Supplementary Table 1. Grade 5 (fatal) adverse events (safety evaluable population). Supplementary Fig. 1. Kaplan–Meier estimates of PFS by treatment group for COO subtypes. A Investigator-assessed PFS by treatment arm in the GCB subgroup, in which a trend towards a better PFS with G-CHOP was observed; B Investigator-assessed PFS by treatment arm in the ABC subgroup, where no difference in PFS between treatment arms was observed; C Investigator-assessed PFS by treatment arm in the unclassified subgroup, in which there was also no difference in PFS between treatment arms.

Published
2020
Full Text
View/download PDF

31. Non-equivalence of Wnt and R-spondin ligands during Lgr5+ intestinal stem-cell self-renewal

Author

Yan, Kelley S., Janda, Claudia Y., Chang, Junlei, Zheng, Grace X. Y., Larkin, Kathryn A., Luca, Vincent C., Chia, Luis A., Mah, Amanda T., Han, Arnold, Terry, Jessica M., Ootani, Akifumi, Roelf, Kelly, Lee, Mark, Yuan, Jenny, Li, Xiao, Bolen, Christopher R., Wilhelmy, Julie, Davies, Paige S., Ueno, Hiroo, von Furstenberg, Richard J., Belgrader, Phillip, Ziraldo, Solongo B., Ordonez, Heather, Henning, Susan J., Wong, Melissa H., Snyder, Michael P., Weissman, Irving L., Hsueh, Aaron J., Mikkelsen, Tarjei S., Garcia, K. Christopher, and Kuo, Calvin J.

Subjects
Ligands (Biochemistry) -- Health aspects, Stem cells -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): Kelley S. Yan [1, 2]; Claudia Y. Janda [3]; Junlei Chang [1]; Grace X. Y. Zheng [4]; Kathryn A. Larkin [1]; Vincent C. Luca [3]; Luis A. Chia [1]; [...]

Published
2017
Full Text
View/download PDF

32. Abstract PO-26: Prognostic significance of Fc gamma receptor IIB expression in the response of previously untreated diffuse large B-cell lymphomas to anti-CD20 monoclonal antibodies: Differing impact of rituximab and obinutuzumab

Author

Hilton, Laura K., primary, Nowicka, Malgorzata, additional, Ashton-Key, Margaret, additional, Hargreaves, Chantal E., additional, Lee, Chern, additional, Foxall, Russell, additional, Carter, Matthew J., additional, Beers, Stephen A., additional, Potter, Kathleen N., additional, Bolen, Christopher R., additional, Klein, Christian, additional, Knapp, Andrea, additional, Mir, Farheen, additional, Rose-Zerilli, Matthew, additional, Burton, Cathy, additional, Klapper, Wolfram, additional, Scott, David W., additional, Sehn, Laurie H., additional, Vitolo, Umberto, additional, Martelli, Maurizio, additional, Trneny, Marek, additional, Slack, Graham W., additional, Farinha, Pedro, additional, Strefford, Jonathan C., additional, Oestergaard, Mikkel Z., additional, Morin, Ryan D., additional, and Cragg, Mark S., additional

Published
2020
Full Text
View/download PDF

34. Follicular Lymphoma Evaluation Index ( FLEX ): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy

Author

Mir, Farheen, primary, Mattiello, Federico, additional, Grigg, Andrew, additional, Herold, Michael, additional, Hiddemann, Wolfgang, additional, Marcus, Robert, additional, Seymour, John F., additional, Bolen, Christopher R., additional, Knapp, Andrea, additional, Nielsen, Tina, additional, and Casulo, Carla, additional

Published
2020
Full Text
View/download PDF

37. Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Author

Kim, Eugene C, primary, Fan, Jinzhen, additional, Bolen, Christopher R, additional, Bazeos, Alexandra, additional, Jiang, Yanwen, additional, Balasubramanian, Sandhya, additional, Balakrishnan, Rama, additional, Knapp, Andrea, additional, Humphrey, Kathryn, additional, Nielsen, Tina G, additional, Venstrom, Jeffrey M., additional, Hernandez, Genevive, additional, and Paulson, Joseph N, additional

Published
2019
Full Text
View/download PDF

38. Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Author

Kater, Arnon P, primary, Wu, Jenny Qun, primary, Dubois, Julie, primary, Bolen, Christopher R, primary, Assaf, Zoe J, primary, Hillmen, Peter, primary, Eichhorst, Barbara F., primary, Eldering, Eric F, primary, Kipps, Thomas J., primary, Langerak, Anton W, primary, Mellink, Clemens, primary, Van Der Kevie-Kersemaekers, Anne-Marie, primary, Owen, Carolyn, primary, Chyla, Brenda J, primary, Punnoose, Elizabeth A, primary, Wang, Jue, primary, Lefebure, Marcus, primary, Boyer, Michelle, primary, Humphrey, Kathryn, primary, Jiang, Yanwen, primary, and Seymour, John F., primary

Published
2019
Full Text
View/download PDF

39. Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Author

Tabari, Ehsan, primary, Lovejoy, Alexander F, primary, Lin, Hai, primary, Bolen, Christopher R, primary, Saelee, Seng Lor, primary, Lefkowitz, Joshua P, primary, Kurtz, David M., primary, Vitazka, Patrik, primary, Venstrom, Jeffrey M., primary, Nielsen, Tina G, primary, Parreira, Joana M, primary, Klass, Daniel M, primary, and Luong, Khai T, primary

Published
2019
Full Text
View/download PDF

40. A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Author

Kostakoglu, Lale, primary, Berchialla, Paola, primary, Dalmasso, Federico, primary, Pierce, Larry A, primary, Vitolo, Umberto, primary, Martelli, Maurizio, primary, Sehn, Laurie H, primary, Trněný, Marek, primary, Nielsen, Tina G, primary, Bolen, Christopher R, primary, Sahin, Deniz, primary, Lee, Calvin, primary, El-Galaly, Tarec Christoffer C., primary, Mattiello, Federico, primary, Kinahan, Paul E, primary, and Chauvie, Stephane, primary

Published
2019
Full Text
View/download PDF

42. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

Author

Hamid, Omid, primary, Molinero, Luciana, additional, Bolen, Christopher R., additional, Sosman, Jeffrey A., additional, Muñoz-Couselo, Eva, additional, Kluger, Harriet M., additional, McDermott, David F., additional, Powderly, John D., additional, Sarkar, Indrani, additional, Ballinger, Marcus, additional, Fassò, Marcella, additional, O'Hear, Carol, additional, Chen, Daniel S., additional, Hegde, Priti S., additional, and Hodi, F. Stephen, additional

Published
2019
Full Text
View/download PDF

44. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

Author

Klanova, Magdalena, primary, Oestergaard, Mikkel Z., additional, Trněný, Marek, additional, Hiddemann, Wolfgang, additional, Marcus, Robert, additional, Sehn, Laurie H., additional, Vitolo, Umberto, additional, Bazeos, Alexandra, additional, Goede, Valentin, additional, Zeuner, Harald, additional, Knapp, Andrea, additional, Sahin, Deniz, additional, Spielewoy, Nathalie, additional, Bolen, Christopher R., additional, Cardona, Andres, additional, Klein, Christian, additional, Venstrom, Jeffrey M., additional, Nielsen, Tina, additional, and Fingerle-Rowson, Günter, additional

Published
2019
Full Text
View/download PDF

47. PD-L1 and tumor-associated macrophages in de novo DLBCL

Author

McCord, Ronald, primary, Bolen, Christopher R., additional, Koeppen, Hartmut, additional, Kadel, Edward E., additional, Oestergaard, Mikkel Z., additional, Nielsen, Tina, additional, Sehn, Laurie H., additional, and Venstrom, Jeffrey M., additional

Published
2019
Full Text
View/download PDF

48. Cell subset prediction for blood genomic studies

Author

Kleinstein Steven H, Uduman Mohamed, and Bolen Christopher R

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Biology (General), QH301-705.5
Abstract

Abstract Background Genome-wide transcriptional profiling of patient blood samples offers a powerful tool to investigate underlying disease mechanisms and personalized treatment decisions. Most studies are based on analysis of total peripheral blood mononuclear cells (PBMCs), a mixed population. In this case, accuracy is inherently limited since cell subset-specific differential expression of gene signatures will be diluted by RNA from other cells. While using specific PBMC subsets for transcriptional profiling would improve our ability to extract knowledge from these data, it is rarely obvious which cell subset(s) will be the most informative. Results We have developed a computational method (Subset Prediction from Enrichment Correlation, SPEC) to predict the cellular source for a pre-defined list of genes (i.e. a gene signature) using only data from total PBMCs. SPEC does not rely on the occurrence of cell subset-specific genes in the signature, but rather takes advantage of correlations with subset-specific genes across a set of samples. Validation using multiple experimental datasets demonstrates that SPEC can accurately identify the source of a gene signature as myeloid or lymphoid, as well as differentiate between B cells, T cells, NK cells and monocytes. Using SPEC, we predict that myeloid cells are the source of the interferon-therapy response gene signature associated with HCV patients who are non-responsive to standard therapy. Conclusions SPEC is a powerful technique for blood genomic studies. It can help identify specific cell subsets that are important for understanding disease and therapy response. SPEC is widely applicable since only gene expression profiles from total PBMCs are required, and thus it can easily be used to mine the massive amount of existing microarray or RNA-seq data.

Published
2011
Full Text
View/download PDF

49. Prediction and Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from Targeted Next-Generation Sequencing

Author

Trabucco, Sally E, primary, Sokol, Ethan S, additional, Moore, Jay A, additional, Maund, Sophia, additional, Frampton, Garrett M, additional, Miller, Vincent A, additional, Venstrom, Jeffrey, additional, Albacker, Lee A, additional, Sehn, Laurie H, additional, Oestergaard, Mikkel Z, additional, and Bolen, Christopher R, additional

Published
2018
Full Text
View/download PDF

50. A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Author

Mir, Farheen, primary, Grigg, Andrew, additional, Herold, Michael, additional, Hiddemann, Wolfgang, additional, Marcus, Robert, additional, Seymour, John F., additional, Bolen, Christopher R, additional, Knapp, Andrea, additional, Launonen, Aino, additional, Mattiello, Federico, additional, Nielsen, Tina, additional, Oestergaard, Mikkel Z, additional, Wenger, Michael, additional, and Casulo, Carla, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results